Autoimmune Encephalitis Subtypes Identified in Rapidly Progressive Dementia

Navigating Rapidly Progressive Dementia: The Role of Autoimmune Encephalitis

Rapidly progressive dementia (RPD) presents a formidable diagnostic challenge, defined by a swift cognitive decline over weeks to months that can arise from a wide range of etiologies [1, 2]. While clinicians often consider neurodegenerative conditions such as Creutzfeldt-Jakob disease, autoimmune encephalitis (AE) is an increasingly recognized and critical differential diagnosis [1, 2]. The significance of AE lies in its potential responsiveness to treatment; unlike many causes of RPD, the prompt initiation of immunomodulatory therapy can lead to substantial clinical improvement and may prevent irreversible neurological injury [1, 3, 4, 5]. However, the varied clinical presentations of AE frequently mimic other dementias, complicating the diagnostic process and risking treatment delays [6, 7]. A recent study provides needed clarity by characterizing the specific clinical features and subtypes of AE that manifest as RPD.

Why Early Identification of Autoimmune Encephalitis Matters in RPD

For any patient with rapidly progressive dementia (RPD), the diagnostic timeline is a critical factor influencing outcomes. This is particularly true when autoimmune encephalitis (AE) is the underlying cause, as early recognition and rapid initiation of immunotherapy are directly linked to improved patient outcomes. This therapeutic window places a significant burden on clinicians to distinguish AE from a broad field of mimics. The ancillary testing required to investigate RPD is often extensive and time-consuming, covering a wide differential that includes neurodegenerative, infectious, metabolic, and neoplastic disorders. Such a comprehensive workup can inadvertently delay the start of essential immunotherapy. Therefore, a more refined method for accurate patient selection based on early clinical features is necessary to help prioritize investigations, reduce diagnostic delays, and ensure patients with AE receive timely and effective treatment.

Study Design and Methodology for Characterizing AE-RPD

To better delineate the clinical profile of autoimmune-mediated dementia, investigators launched a prospective multicenter observational cohort study in the Netherlands. This design allows for the collection of real-world data from a diverse patient population. The study, running from December 2019 to December 2024, enrolled adult patients with RPD, defined as dementia with an onset within one year of the first symptom. The researchers pursued two main goals: first, to establish the frequency of specific autoimmune encephalitis (AE) subtypes in this RPD cohort (termed AE-RPD), and second, to characterize their presenting subphenotypes, meaning the constellation of symptoms beyond dementia. To achieve this, a panel of three neurologists reviewed detailed clinical features and ancillary testing data for each participant. Crucially, serum and cerebrospinal fluid (CSF) were analyzed for neuronal and glial autoantibodies to definitively identify an autoimmune basis for the dementia.

Key Autoimmune Encephalitis Subtypes in RPD

The investigation confirmed that autoimmune etiologies are a vital consideration in the RPD workup, finding that AE was the most common treatment-responsive cause of RPD in this cohort. Among patients with AE-driven RPD, two specific conditions were predominant: anti-leucine-rich, glioma-inactivated 1 (LGI1) encephalitis and autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy. This finding helps narrow the focus for clinicians evaluating patients who may benefit from immunotherapy. The study also provided a key clinical insight by examining the subgroup of AE-RPD patients who did not present with seizures. Within this non-seizure group, autoimmune GFAP astrocytopathy was the most frequent subtype, identified in 8 of 31 patients (26%). The clinical presentation of these patients was distinct, suggesting a specific diagnostic clue: this form of astrocytopathy most often manifested with prominent psychotic features (4 of 8 patients; 50%) or movement disorders (4 of 8 patients; 50%). This suggests that in a patient with RPD without seizures, the emergence of new-onset psychosis or a movement disorder should elevate suspicion for autoimmune GFAP astrocytopathy, a treatable condition.

References

1. Lei M, Cao L, Liu R, et al. The evolving etiologies of rapidly progressive dementia: a systematic review.. Translational psychiatry. 2025. doi:10.1038/s41398-025-03777-7

2. Guillen JFC, Cristalli CAA, Berrios W, et al. Etiologies of rapidly progressive dementias: A systematic review and meta-analysis of causes in worldwide and Latin America.. Journal of Alzheimer's disease reports. 2025. doi:10.1177/25424823251314505

3. Steenhoven RWV, Bastiaansen AEM, Kerstens J, et al. Autoimmune Encephalitis as Treatment-Responsive Cause of Rapidly Progressive Dementia: A Multicenter Prospective Cohort Study.. Neurology. 2026. doi:10.1212/WNL.0000000000214933

4. Teng Y, Li T, Zhi-zhong Y, et al. Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review. Frontiers in Neurology. 2022. doi:10.3389/fneur.2021.791014

5. Zuliani L, Graus F, Giometto B, Bien CG, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. Journal of Neurology Neurosurgery & Psychiatry. 2012. doi:10.1136/jnnp-2011-301237

6. Bastiaansen AE, Steenhoven RWV, Vaarwerk EST, et al. Antibodies Associated With Autoimmune Encephalitis in Patients With Presumed Neurodegenerative Dementia. Neurology Neuroimmunology & Neuroinflammation. 2023. doi:10.1212/nxi.0000000000200137

7. Gomes ILDS, Almeida S, Miranda GL, et al. Unveiling the fog: rapid cognitive decline in an elderly patient resolved with innovative therapies for seronegative autoimmune encephalitis. Arquivos de Neuro-Psiquiatria. 2024. doi:10.5327/cbn241723